Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14712598.2019.1570498 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Relationship Between Short-Term Outcomes and PD-L1 Expression Based on Combined Positive Score and Tumor Proportion Score in Recurrent or Metastatic Head and Neck Cancers Treated With Anti-PD-1 Antibody Monotherapy.
Cancer Rep (Hoboken)
January 2025
Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Background: PD-L1 expression in tumors and immune cells is a biomarker for the efficacy of anti-PD-1 antibody (APA) therapy across diverse cancers. Based on the results from the KEYNOTE-048 trial, pembrolizumab monotherapy is indicated for platinum-sensitive recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC) with a positive combined positive score (CPS). Conversely, nivolumab is utilized for platinum-pretreated R/M-HNSCC regardless of the positive tumor proportion score (TPS) following the results of the CheckMate-141; however, its subgroup analysis indicated that TPS-positive population tended to have a relatively high overall response rate and progression-free survival (PFS).
View Article and Find Full Text PDFThe efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab versus nivolumab in a real-world setting.
Br J Dermatol
November 2024
Service d'onco-dermatologie, Hôpital Saint Louis APHP, 1 avenue Claude Vellefaux, 75010 Paris.
Background: The Checkmate 067 randomized controlled trial, published in 2015, demonstrated improved progression-free survival and numerically, although not statistically, superior overall survival for ipilimumab + nivolumab. The objective of this study was to compare the efficacy and safety of nivolumab to ipilimumab + nivolumab as first-line treatment for metastatic melanoma in a real-world setting.
Methods: Patients were prospectively included in the French Melbase cohort from 2013 to 2022.
Effect of performance status on the therapeutic effect of nivolumab in recurrent or metastatic squamous cell carcinoma of the head and neck.
Eur Arch Otorhinolaryngol
November 2024
Department of Otolaryngology-Head and Neck Surgery, Nara Medical University, 840 Shijo-Cho, Kashihara-City, Nara, 634-8521, Japan.
Background: Systemic chemotherapy is the primary treatment strategy for recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN). Therapeutic strategies are changing considerably with the introduction of molecular-targeted and immune checkpoint inhibitor (ICI) therapies in addition to conventional cytotoxic therapy. The CheckMate-141 and KEYNOTE-048 trials have enabled the use of ICIs as first-line treatment to improve the overall prognosis of RM-SCCHN.
View Article and Find Full Text PDFEstimating cure proportion in cancer clinical trials using flexible parametric cure models.
BJC Rep
August 2024
Institute of Statistical Mathematics, Tokyo, Japan, and Data Science and AI Innovation Research Promotion Center, Shiga University, Shiga, Japan.
Background: In the context of survival analysis in recent cancer clinical trials, there has been an increasing interest in the proportion of patients who are not susceptible to the event, known as the cure proportion. To estimate it, cure models implicitly specify the time point when patients are considered cured, although the impact of the cure point position on cure proportion estimates is unclear.
Methods: Sensitivity of cure proportion estimates to the knot number and placement in flexible parametric cure models was examined using data from a clinical trial of CheckMate 141, an immuno-oncology compound.
Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG).
Eur Arch Otorhinolaryngol
September 2024
Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Objectives: Head and neck cancers (HNCs) represent a significant global health concern due to high morbidity and mortality rates. Despite therapeutic advances, the prognosis for advanced or recurrent cases remains challenging. Nivolumab obtained approval for recurrent or metastatic HNC based on the Phase III CheckMate 141 trial.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!